Immediate Impact
11 standout
Citing Papers
Emerging Therapeutic Strategies to Overcome Drug Resistance in Cancer Cells
2024 Standout
The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development
2024 Standout
Works of Arif Awan being referenced
Enfortumab vedotin (EV) in triple-negative breast cancer (TNBC) and HR+/HER2- breast cancer (BC) cohorts of EV-202.
2024
Endocrine Therapy for Breast Cancer in the Primary Care Setting
2018
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Arif Awan | 177 | 86 | 49 | 54 | 46 | 273 | |
| Ajay Bapna | 111 | 74 | 28 | 48 | 36 | 321 | |
| Sailaja Kamaraju | 118 | 30 | 47 | 12 | 43 | 286 | |
| Judit Kocsis | 158 | 74 | 22 | 58 | 37 | 329 | |
| M. Martín Jiménez | 191 | 126 | 75 | 29 | 55 | 308 | |
| Chase J. Wehrle | 94 | 44 | 18 | 19 | 68 | 249 | |
| Ushma S. Neill | 82 | 28 | 14 | 20 | 43 | 334 | |
| Utku Oflazoğlu | 142 | 40 | 44 | 15 | 39 | 291 | |
| Sayaka Kuba | 99 | 67 | 54 | 22 | 43 | 332 | |
| Liangying Gan | 60 | 41 | 13 | 9 | 37 | 251 | |
| Sema Sezgin Göksu | 191 | 105 | 56 | 22 | 46 | 334 |
All Works
Login with ORCID to disown or claim papers
Loading papers...